中国组织工程研究与临床康复
中國組織工程研究與臨床康複
중국조직공정연구여림상강복
JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH
2010年
4期
706-709
,共4页
心血管支架%再狭窄%C-反应蛋白%冠状动脉粥样硬华性心脏病%药物涂层
心血管支架%再狹窄%C-反應蛋白%冠狀動脈粥樣硬華性心髒病%藥物塗層
심혈관지가%재협착%C-반응단백%관상동맥죽양경화성심장병%약물도층
背景:心血管支架作为一种异体物质,置入后存在明显的炎症反应过程,主要表现在凝血系统的激活以及炎性标志物血清C-反应蛋白的显著升高.目的:总结探讨支架置入后冠状动脉粥样硬化性心脏病患者炎症反应及C-反应蛋白的变化.方法:应用计算机检索中文期刊全文数据库1990/2009相关文献,检索词为"心血管支架,C-反应蛋白,炎症反应",同时检索PubMed数据库1990/2009相关文献,检索词为"cardiovascular stent on plasma,c-reactive protein".结果与结论:药物涂层支架以金属支架为载体携带药物到达血管损伤局部,使药物在较长的时间内充分释放到血管壁内,减少支架置入后再狭窄的发生.抗炎药物涂层支架主要药物为地塞米松、甲泼尼龙等.抗迁移、抗增生药物涂层支架主要药物为雷帕霉素、紫杉醇、放线菌素D等.支持内膜愈合的药物涂层支架主要药物为雌二醇等.经皮冠状动脉支架置入可诱导和加重局部炎症反应,这对血管内皮的增生与再狭窄有重要影响.反映急性炎症反应的敏感指标如血清C-反应蛋白的浓度对于经皮冠状动脉支架置入后心血管事件的发生有预测价值.冠状动脉内支架置入可显著升高血浆C-反应蛋白水平,所以应充分认识炎症反应及血浆C-反应蛋白、细胞因子的变化对防止心血管支架置入后再狭窄起到的重要作用,及早进行预防及干预,从而减少再狭窄率,提高介入治疗效果.
揹景:心血管支架作為一種異體物質,置入後存在明顯的炎癥反應過程,主要錶現在凝血繫統的激活以及炎性標誌物血清C-反應蛋白的顯著升高.目的:總結探討支架置入後冠狀動脈粥樣硬化性心髒病患者炎癥反應及C-反應蛋白的變化.方法:應用計算機檢索中文期刊全文數據庫1990/2009相關文獻,檢索詞為"心血管支架,C-反應蛋白,炎癥反應",同時檢索PubMed數據庫1990/2009相關文獻,檢索詞為"cardiovascular stent on plasma,c-reactive protein".結果與結論:藥物塗層支架以金屬支架為載體攜帶藥物到達血管損傷跼部,使藥物在較長的時間內充分釋放到血管壁內,減少支架置入後再狹窄的髮生.抗炎藥物塗層支架主要藥物為地塞米鬆、甲潑尼龍等.抗遷移、抗增生藥物塗層支架主要藥物為雷帕黴素、紫杉醇、放線菌素D等.支持內膜愈閤的藥物塗層支架主要藥物為雌二醇等.經皮冠狀動脈支架置入可誘導和加重跼部炎癥反應,這對血管內皮的增生與再狹窄有重要影響.反映急性炎癥反應的敏感指標如血清C-反應蛋白的濃度對于經皮冠狀動脈支架置入後心血管事件的髮生有預測價值.冠狀動脈內支架置入可顯著升高血漿C-反應蛋白水平,所以應充分認識炎癥反應及血漿C-反應蛋白、細胞因子的變化對防止心血管支架置入後再狹窄起到的重要作用,及早進行預防及榦預,從而減少再狹窄率,提高介入治療效果.
배경:심혈관지가작위일충이체물질,치입후존재명현적염증반응과정,주요표현재응혈계통적격활이급염성표지물혈청C-반응단백적현저승고.목적:총결탐토지가치입후관상동맥죽양경화성심장병환자염증반응급C-반응단백적변화.방법:응용계산궤검색중문기간전문수거고1990/2009상관문헌,검색사위"심혈관지가,C-반응단백,염증반응",동시검색PubMed수거고1990/2009상관문헌,검색사위"cardiovascular stent on plasma,c-reactive protein".결과여결론:약물도층지가이금속지가위재체휴대약물도체혈관손상국부,사약물재교장적시간내충분석방도혈관벽내,감소지가치입후재협착적발생.항염약물도층지가주요약물위지새미송、갑발니룡등.항천이、항증생약물도층지가주요약물위뢰파매소、자삼순、방선균소D등.지지내막유합적약물도층지가주요약물위자이순등.경피관상동맥지가치입가유도화가중국부염증반응,저대혈관내피적증생여재협착유중요영향.반영급성염증반응적민감지표여혈청C-반응단백적농도대우경피관상동맥지가치입후심혈관사건적발생유예측개치.관상동맥내지가치입가현저승고혈장C-반응단백수평,소이응충분인식염증반응급혈장C-반응단백、세포인자적변화대방지심혈관지가치입후재협착기도적중요작용,급조진행예방급간예,종이감소재협착솔,제고개입치료효과.
BACKGROUND: The inflammatory reaction occurs following implantation of cardiovascular stent with manifestations of the activation of blood coagulation system and dramatically increasing of inflammatory markers serum C-reactive protein. OBJECTIVE: To explore the changes of inflammatory reaction and C-reactive protein in coronary artery disease patients following cardiovascular stent implantation.METHODS: A computer-based online search of CNKI (1990/2009) and PubMed databases (1990/2009) was performed for related articles with the key words "cardiovascular stent, C-reactive protein" in Chinese and "cardiovascular stent on plasma, C-reactive protein" in English.RESULTS AND CONCLUSION: Based on the metal stents, drug-eluting stents can transfer the active drugs to the damaged vessels, release them into the vascular wall and inhibit the in-stent restenosis, Main drugs of anti-inflammatory drug-eluting stent include dexamethasone and methylprednisolone. Main drugs of anti-migratory and anti-proliferative drug-eluting stent includerapamycin, paclitaxel and actinomycin D. Main drugs of supporting intima concrescence stent include estradiol. Coronary artery stents implantation can induce and aggravate local inflammation reaction, which have important infection for vascular endodermis hyperplasia and restenosis occurrence. Some impressible index for inflammation reaction, such as levels of C-reactive protein,have predictive value for vascular events following the coronary artery stents implantation. A significant increase in plasma C-reactive protein after coronary stenting has been observed following stent implantation. Therefore, understanding of inflammatory reaction and C-reactive protein, as well as cytokine changes is important for preventing restenosis, early treatment of restenosis, as well as improving treatment effect.